s6y

Bellerophon Therapeutics, Inc.

CIK
1600132
Industry
Pharmaceutical Preparations
Formerly
Bellerophon Therapeutics LLC

Financials 39

  1. 10-Q Quarterly Report for period ending Sep 30, 2023
  2. 10-Q Quarterly Report for period ending Jun 30, 2023
  3. 10-Q Quarterly Report for period ending Mar 31, 2023
  4. 10-K Annual Report for period ending Dec 31, 2022
  5. 10-Q Quarterly Report for period ending Sep 30, 2022
  6. 10-Q Quarterly Report for period ending Jun 30, 2022
  7. 10-Q Quarterly Report for period ending Mar 31, 2022
  8. 10-K Annual Report for period ending Dec 31, 2021
  9. 10-Q Quarterly Report for period ending Sep 30, 2021
  10. 10-Q Quarterly Report for period ending Jun 30, 2021

All 39 financials filings

News 160

  1. 8-K Current report filing
  2. 8-K Current report filing
  3. 8-K Current report filing
  4. 8-K Current report filing
  5. 8-K Current report filing
  6. 8-K Current report filing
  7. 8-K Current report filing
  8. 8-K Current report filing
  9. 8-K Current report filing
  10. 8-K Current report filing

All 160 news filings

Ownership 322

  1. SC 13G/A Major Shareholders
  2. SC 13G/A Major Shareholders
  3. SC 13G Major Shareholders
  4. SC 13D/A Major Shareholders
  5. SC 13D/A Major Shareholders
  6. 4 Statement of changes in beneficial ownership of securities
  7. SC 13G/A Major Shareholders
  8. 4 Statement of changes in beneficial ownership of securities
  9. 4 Statement of changes in beneficial ownership of securities
  10. 4 Statement of changes in beneficial ownership of securities

All 322 ownership filings

Prospectus 51

  1. RW Registration Withdrawal Request
  2. S-8 POS Post-effective amendment to a S-8 registration statement
  3. S-8 POS Post-effective amendment to a S-8 registration statement
  4. S-8 POS Post-effective amendment to a S-8 registration statement
  5. S-8 POS Post-effective amendment to a S-8 registration statement
  6. S-8 POS Post-effective amendment to a S-8 registration statement
  7. S-8 POS Post-effective amendment to a S-8 registration statement
  8. S-8 POS Post-effective amendment to a S-8 registration statement
  9. S-8 POS Post-effective amendment to a S-8 registration statement
  10. S-8 Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

All 51 prospectus filings

Proxies 24

  1. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
  2. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
  3. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
  4. DEF 14A Definitive proxy statements
  5. PRE 14A Preliminary proxy statement not related to a contested matter or merger/acquisition
  6. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
  7. DEF 14A Definitive proxy statements
  8. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
  9. DEF 14A Definitive proxy statements
  10. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.

All 24 proxies filings

Other 47

  1. 15-12G Notice of termination of registration of a class of securities under Section 12(g)
  2. SCHEDULE 13G
  3. SCHEDULE 13G
  4. 25-NSE Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities
  5. EFFECT Notice of Effectiveness
  6. CORRESP A correspondence can be sent as a document with another submission type or can be sent as a separate submission.
  7. 144 Filing for proposed sale of securities under Rule 144
  8. UPLOAD Letter (PDF)
  9. 144 Filing for proposed sale of securities under Rule 144
  10. ARS Annual report to security holders

All 47 other filings